|
|
|
Volumn 7, Issue 9, 2009, Pages 588-589
|
|
Lessons learned from the development of kinase inhibitors
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABELSON KINASE;
B RAF KINASE;
BCR ABL PROTEIN;
DASATINIB;
DNA;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
ERLOTINIB;
IMATINIB;
MAMMALIAN TARGET OF RAPAMYCIN;
NILOTINIB;
PLX 4032;
PROTEIN KINASE;
PROTEIN KINASE INHIBITOR;
RAPAMYCIN;
SCATTER FACTOR RECEPTOR;
SORAFENIB;
SUNITINIB;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
VASCULOTROPIN;
ANTIINFLAMMATORY ACTIVITY;
ARTICLE;
BREAST CANCER;
CANCER SURVIVAL;
CHRONIC MYELOID LEUKEMIA;
CLINICAL TRIAL;
DNA SEQUENCE;
DRUG INDICATION;
DRUG INDUSTRY;
DRUG PROTEIN BINDING;
DRUG RESEARCH;
DRUG SCREENING;
DRUG SELECTIVITY;
DRUG TARGETING;
DRUG TOLERABILITY;
ENZYME ACTIVITY;
ENZYME INHIBITION;
GENE EXPRESSION PROFILING;
GENE MUTATION;
HIGH THROUGHPUT SCREENING;
HUMAN;
INDIVIDUALIZATION;
KIDNEY GRAFT REJECTION;
KIDNEY TRANSPLANTATION;
LUNG CANCER;
MALIGNANT NEOPLASTIC DISEASE;
MELANOMA;
MUTATIONAL ANALYSIS;
PATIENT CARE;
PATIENT SELECTION;
PHARMACOGENETICS;
ROBOTICS;
ANIMALS;
DRUG DISCOVERY;
DRUG RESISTANCE, NEOPLASM;
HUMANS;
PROTEIN KINASE INHIBITORS;
|
|
EID: 70349682746
PISSN: 15430790
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (3)
|
|
References (2)
|
